Claims
- 1. A composition to treat Parkinsonism, comprising an inert carrier and, as an active ingredient, an amount, which is effective to treat Parkinsonism, of a compound selected from the group consisting of a 2,3-dihydroimidazo[2,1-b]benzothiazole which may structurally be represented by the formula ##STR41## and the pharmaceutically acceptable acid addition salts thereof, the pharmaceutically acceptable imidazo[2,1-b]benzothiazolium salts of formula ##STR42## and metal salt complexes thereof with a transition metal salt, wherein: R.sup.1 and R.sup.3 are each independently selected from the group consisting of hydrogen and lower alkyl;
- R.sup.2 and R.sup.4 are each independently selected from the group consisting of hydrogen, lower alkyl, aryl, aryl-lower alkyl, lower alkyloxy-lower alkyl or aryloxy-lower alkyl;
- R.sup.5, R.sup.6, R.sup.7 and R.sup.8 are each independently selected from the group consisting of hydrogen; halo; nitro; alkyl having from 1 to 20 carbon atoms; cycloalkyl having from 3 to 6 carbon atoms; hydroxy; lower alkyloxy; aryloxy; .alpha.-hydroxy-arylmethyl; amino; mono- and dialkyl-amino; mono-, di- and trihalo-lower alkylamino; lower alkenylamino; lower alkynylamino; (aryllower alkyl)amino; (lower alkyloxy-lower alkyl)amino; (hydroxy-lower alkyl)amino; (aryloxy-lower alkyl)amino; [mono- and di(lower alkyl)amino-lower alkyl]amino; lower alkanoylamino; N-(lower alkyl)lower alkanoylamino; aminocarbonylamino; (1-lower alkyl-4-piperidinyl)amino; cycloalkylamino wherein said cycloalkyl represents a mino-, bi-, tri- or tetracyclic hydrocarbon radical having from 3 to 10 carbon atoms; and a radical of the formula ##STR43## wherein R.sup.10 is selected from the group consisting of hydrogen, lower alkyl, lower alkenyl and lower alkynyl; or, when taken together R.sup.5 and R.sup.6, R.sup.6 and R.sup.7, or R.sup.7 and R.sup.8 may form a tri- or tetramethylene bridge or complete a fused benzene nucleus;
- R.sup.9 is a member selected from the group consisting of lower alkyl, lower alkenyl, lower alkynyl and aryllower alkyl; and
- X is a pharmaceutically acceptable anion and n represents the valency of the anion;
- wherein aryl as used in the foregoing definitions is phenyl, optionally substituted with 1 to 3 substituents each independently selected from the group consisting of halo, lower alkyl, lower alkyloxy and trifluoromethyl; and aroyl is arylcarbonyl.
- 2. A composition of treat Parkinsonism, comprising an inert carrier and, as an active ingredient, an amount, which is effective to treat Parkinsonism, of a compound selected from the group consisting of N-ethyl-2,3-dihydroimidazo[2,1-b]benzothiazol-6-amine, the pharmaceutically acceptable acid additions salts thereof, the corresponding imidazo[2,1-b]benzothiazolium salts and the metal salt complexes thereof.
- 3. A method of treating Parkinsonism in warm-blooded animals, which comprises the systemic administration to said warm-blooded animals, in need of same, or an amount, which is effective to treat Parkinsonism, of a compound selected from the group consisting of a 2,3-dihydroimidazo[2,1-b]benzothiazole which may structurally be represented by the formula ##STR44## and the pharmaceutically acceptable acid addition salts thereof, the pharmaceutically acceptable imidazo[2,1-b]benzothiazolium salts of formula ##STR45## and metal salt complexes thereof with a transition metal salt, wherein: R.sup.1 and R.sup.3 are each independently selected from the group consisting of hydrogen and lower alkyl;
- R.sup.2 and R.sup.4 are each independently selected from the group consisting of hydrogen, lower alkyl, aryl, aryl-lower alkyl, lower alkyloxy-lower alkyl or aryloxy-lower alkyl;
- R.sup.5, R.sup.6, R.sup.7 and R.sup.8 are each independently selected from the group consisting of hydrogen; halo; nitro; alkyl having from 1 to 20 carbon atoms; cycloalkyl having from 3 to 6 carbon atoms; hydroxy; lower alkyloxy; aryloxy; .alpha.-hydroxy-arylmethyl; amino; mono- and dialkyl-amino; mono-, di- and trihalo-lower alkylamino; lower alkenylamino; lower alkynylamino; (aryl-lower alkyl)amino; (lower alkyloxy-lower alkyl)amino; (hydroxylower alkyl)amino; (aryloxy-lower alkyl)amino; [mono- and di(lower alkyl)amino-lower alkyl]amino; lower alkanoylamino; N-(lower alkyl)-lower alkanoylamino; aminocarboxylamino; (1-lower alkyl-4-piperidinyl)amino;cycloalkylamino wherein said cycloalkyl represents a mono-, bi-, tri- or tetracyclic hydrocarbon radical having from 3 to 10 carbon atoms; and a radical of the formula ##STR46## wherein R.sup.10 is selected from the group consisting of hydrogen, lower alkyl, lower alkenyl and lower alkynyl; or, when taken together R.sup.5 and R.sup.6, R.sup.6 and R.sup.7, or R.sup.7 and R.sup.8 may form a tri- or tetramethylene bridge or complete a fused benzene nucleus;
- R.sup.9 is a member selected from the group consisting of lower alkyl, lower alkenyl, lower alkynyl and aryl lower alkyl; and
- X is a pharmaceutically acceptable anion and n represents the valency of the anion;
- wherein aryl as used in the foregoing definitions is phenyl, optionally substituted with 1 to 3 substituents each independently selected from the group consisting of halo, lower alkyl, lower alkyloxy and trifluoromethyl; and aroyl is arylcarbonyl.
Parent Case Info
This is a division of application Ser. No. 50,734 filed June 21, 1979 now U.S. Pat. No. 4,262,004.
US Referenced Citations (5)
Non-Patent Literature Citations (4)
Entry |
CA 82, p. 509, 31326h (1975) Abstracting Russian Patent No. 436058. |
Ogura et al, Chem. Pharm. Bull. 18 (10), 1981-1986 (1970). |
Garrick et al, Chem. and Ind. 1970, 39, 1261-1262. |
CA 91, p. 626, 39390f (1979). |
Divisions (1)
|
Number |
Date |
Country |
Parent |
50734 |
Jun 1979 |
|